Literature DB >> 12851484

How cancers escape their oncogene habit.

Sylvie Giuriato1, Dean W Felsher.   

Abstract

Many recent reports demonstrate that at least initially, the inactivation of an oncogene can induce sustained regression of even a highly invasive and genetically complex cancer. However, upon prolonged oncogene inactivation, some cancers ultimately relapse, becoming independent of the very oncogene that initiated the process of tumorigenesis. Understanding the specific mechanisms by which cancers can escape dependence upon a particular oncogene will be critical to anticipate mechanisms by which human cancers will evade therapies that target individual oncogenes. Thereby, more effective strategies will be developed to clinically treat cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12851484

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  7 in total

1.  MYC Inactivation Elicits Oncogene Addiction through Both Tumor Cell-Intrinsic and Host-Dependent Mechanisms.

Authors:  Dean W Felsher
Journal:  Genes Cancer       Date:  2010-06

2.  Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch.

Authors:  Sylvie Giuriato; Sandra Ryeom; Alice C Fan; Pavan Bachireddy; Ryan C Lynch; Matthew J Rioth; Jan van Riggelen; Andrew M Kopelman; Emmanuelle Passegué; Flora Tang; Judah Folkman; Dean W Felsher
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-20       Impact factor: 11.205

Review 3.  Harnessing preclinical mouse models to inform human clinical cancer trials.

Authors:  David H Gutmann; Kim Hunter-Schaedle; Kevin M Shannon
Journal:  J Clin Invest       Date:  2006-04       Impact factor: 14.808

Review 4.  Using neurofibromatosis-1 to better understand and treat pediatric low-grade glioma.

Authors:  David H Gutmann
Journal:  J Child Neurol       Date:  2008-10       Impact factor: 1.987

5.  Mad2-induced chromosome instability leads to lung tumour relapse after oncogene withdrawal.

Authors:  Rocio Sotillo; Juan-Manuel Schvartzman; Nicholas D Socci; Robert Benezra
Journal:  Nature       Date:  2010-02-21       Impact factor: 49.962

6.  Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis.

Authors:  Catherine M Shachaf; Omar D Perez; Sawsan Youssef; Alice C Fan; Sailaja Elchuri; Matthew J Goldstein; Amy E Shirer; Orr Sharpe; Joy Chen; Dennis J Mitchell; Maria Chang; Garry P Nolan; Lawrence Steinman; Dean W Felsher
Journal:  Blood       Date:  2007-07-10       Impact factor: 22.113

7.  Tetracycline regulated systems in functional oncogenomics.

Authors:  Arkadiusz Welman; Jane Barraclough; Caroline Dive
Journal:  Transl Oncogenomics       Date:  2007-03-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.